Chroma Medicine leverages genomic medicine to develop therapeutics able to control gene expression. With the ability to target parts of the genome, the goal is relief for patients suffering from severe illnesses. Chroma Medicine was founded in 2021 by Angelo Lombardo Ph.D., Luigi Naldini Ph.D., David Liu Ph.D., and Jonathan Weissman Ph.D. and is headquartered in Boston, MA.

Register for Details

For more details on financing and valuation of private companies similar to Chroma Medicine before its , register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Chroma Medicine

To invest in Chroma Medicine pre-IPO

Can you invest in Chroma Medicine pre-IPO?

You can no longer invest in Chroma Medicine with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Chroma Medicine before it goes public?

You can no longer sell shares of Chroma Medicine on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Chroma Medicine shares?

Forge can no longer determine the value of Chroma Medicine shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Chroma Medicine a publicly traded company?

Chroma Medicine became a public company following its M&A on 12/11/2024 and is now a publicly traded company.

To learn more about Chroma Medicine potential IPO

Will Chroma Medicine go IPO?

Chroma Medicine became a public company following its M&A on 12/11/2024.

What is Chroma Medicine’s IPO price?

The IPO price of Chroma Medicine is not currently available.

When was Chroma Medicine founded?

Chroma Medicine was founded in 2020.

What is Chroma Medicine funding to date?

Chroma Medicine has raised $262MM to date.

Who are Chroma Medicine’s major investors?

Janus Henderson Investors
Casdin Vapital
Osage University Partners
Casdin Capital
Sofinnova Investments
T. Rowe Price Associates
Cormorant Asset Management
Sofinnova Partners
Arch Venture Partners
T Rowe Price
Dcvc Bio
Alexandria Venture Investments
Mubadala Capital
Omega Funds
Newpath Partners
Atlas Venture
Wellington Management
Undisclosed Investors
Sixth Street
Dcvc

Chroma Medicine Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/01/2023 Series B $135MM $xx.xx $450.56MM Alexandria Venture Investments, Arch Venture Partners, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Dcvc Bio, Janus Henderson Investors, Mubadala Capital, Newpath Partners, Omega Funds, Osage University Partners, Sixth Street, Sofinnova Partners, T Rowe Price, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
51,923,077
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Dcvc Bio, Janus Henderson Investors, Mubadala Capital, Newpath Partners, Omega Funds, Osage University Partners, Sixth Street, Sofinnova Partners, T Rowe Price, Wellington Management
11/17/2021 Series A $100.7MM $xx.xx $254.7MM Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Omega Funds, T. Rowe Price Associates, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
47,499,994
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Omega Funds, T. Rowe Price Associates, Wellington Management
05/27/2020 Series Seed $26.3MM $xx.xx $75.16MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
24,583,572
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.